These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 21685772)

  • 1. A new use for Xifaxan.
    Belavic JM
    Nurse Pract; 2011 Jul; 36(7):8-9. PubMed ID: 21685772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal treatment of hepatic encephalopathy.
    Waghray A; Waghray N; Kanna S; Mullen K
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):55-70. PubMed ID: 24632768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hepatic encephalopathy: role of rifaximin.
    Zeneroli ML; Avallone R; Corsi L; Venturini I; Baraldi C; Baraldi M
    Chemotherapy; 2005; 51 Suppl 1():90-5. PubMed ID: 15855752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rifaximin (Xifaxan 550) for hepatic encephalopathy.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):87. PubMed ID: 21045761
    [No Abstract]   [Full Text] [Related]  

  • 5. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
    Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
    Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolving concepts: the negative effect of minimal hepatic encephalopathy and role for prophylaxis in patients with cirrhosis.
    Prakash RK; Kanna S; Mullen KD
    Clin Ther; 2013 Sep; 35(9):1458-73. PubMed ID: 23972578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of Hepatic Encephalopathy: A Primer.
    Jawaro T; Yang A; Dixit D; Bridgeman MB
    Ann Pharmacother; 2016 Jul; 50(7):569-77. PubMed ID: 27126547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic encephalopathy.
    Khungar V; Poordad F
    Clin Liver Dis; 2012 May; 16(2):301-20. PubMed ID: 22541700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ammonia abolishers: antibiotics for hepatic encephalopathy.
    Felicilda-Reynaldo RF
    Medsurg Nurs; 2012; 21(3):173-5; quiz 176. PubMed ID: 22866441
    [No Abstract]   [Full Text] [Related]  

  • 11. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
    Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatic encephalopathy: focus on antibiotic therapy.
    Festi D; Vestito A; Mazzella G; Roda E; Colecchia A
    Digestion; 2006; 73 Suppl 1():94-101. PubMed ID: 16498257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of an experimental rat model of hyperammonemic encephalopathy and evaluation of the effects of rifaximin.
    Tamaoki S; Suzuki H; Okada M; Fukui N; Isobe M; Saito T
    Eur J Pharmacol; 2016 May; 779():168-76. PubMed ID: 26980242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis.
    Kawaguchi T; Taniguchi E; Sata M
    Nutr Clin Pract; 2013 Oct; 28(5):580-8. PubMed ID: 23945292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapy of hepatic encephalopathy in cirrhosis.
    Romero-Gómez M
    Expert Opin Pharmacother; 2010 Jun; 11(8):1317-27. PubMed ID: 20384539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of hepatic encephalopathy with non-absorbable antibiotics.
    Festi D; Mazzella G; Parini P; Ronchi M; Cipolla A; Orsini M; Sangermano A; Bazzoli F; Aldini R; Roda E
    Ital J Gastroenterol; 1992; 24(9 Suppl 2):14-6. PubMed ID: 1486194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of overt hepatic encephalopathy.
    Khungar V; Poordad F
    Clin Liver Dis; 2012 Feb; 16(1):73-89. PubMed ID: 22321466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
    Irimia R; Trifan A
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.